DaVita Target Price

See DaVita's analyst price targets ($230) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$179.17

Average Target Price

$227.36

26.9% upside

11 analysts in the last 4 months

High: $270 | Low: $194

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-07	Truist Financial	$215	20% upside
2026-08-07	Oppenheimer	$220	22.8% upside
2026-08-07	Raymond James	$220	22.8% upside
2026-08-05	Deutsche BankPito Chickering	$265	47.9% upside
2026-08-05	BarclaysAndrew Mok	$224	25% upside
2026-07-14	Truist Financial	$250	39.5% upside
2026-07-10	UBS	$270	50.7% upside
2026-07-08	Barclays	$218	21.7% upside
2026-05-08	Truist Financial	$205	14.4% upside
2026-05-07	BarclaysAndrew Mok	$194	8.3% upside
2026-05-06	Deutsche BankPito Chickering	$220	22.8% upside
2026-02-05	Truist Financial	$158	11.8% downside
2026-02-04	UBS	$190	6% upside
2026-02-03	Barclays	$158	11.8% downside
2025-10-30	Barclays	$143	20.2% downside
2025-10-14	Truist FinancialDavid MacDonald	$140	21.9% downside
2025-10-09	BarclaysAndrew Mok	$149	16.8% downside
2025-08-08	Truist FinancialDavid MacDonald	$148	17.4% downside
2025-02-21	BernsteinLisa Bedell Clive	$184	2.7% upside
2024-08-07	Bank of America SecuritiesKevin Fischbeck	$145	19.1% downside
2024-05-06	BarclaysAndrew Mok	$150	16.3% downside
2022-10-31	BarclaysSarah James	$81	54.8% downside
2022-08-19	UBSAndrew Mok	$117	34.7% downside
2022-06-28	Truist FinancialDavid MacDonald	$90	49.8% downside

DaVita (DVA) FAQ

DaVita's target price stands at $230. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $230 for DVA implies 26.9% upside versus today's price ($179.17). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how DaVita's target price evolved across reporting periods, while the comparison chart places DVA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. DaVita's reading of $230 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.